Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503277 | 1.00 | EGLN1 (0.77) | EGLN1 | |
| SCHEMBL28807641 | 0.91 | EGLN1 (0.71) | EGLN1 | |
| SCHEMBL12502995 | 0.85 | EGLN1 (0.79) | EGLN1 | |
| SCHEMBL12502871 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL12502874 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL12502673 | 0.84 | EGLN1 (0.76) | EGLN1 | |
| SCHEMBL12502908 | 0.84 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL12502928 | 0.82 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL12502693 | 0.82 | EGLN1 (0.72) | EGLN1 | |
| SCHEMBL18043883 | 0.81 | EGLN1 (1.00) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670750-B1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR | FIBROGEN INC (US) | 2016-09-14 | — | — | EP | claimed |
| CN-103608346-B | As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors | 菲布罗根有限公司 | 2016-06-15 | — | — | CN | claimed |
| US-9271970-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2016-03-01 | — | — | US | claimed |
| US-20150174110-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. | 2015-06-25 | — | — | US | claimed |
| US-8921389-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20140088101-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2014-03-27 | — | — | US | claimed |
| CN-103608346-A | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN INC | 2014-02-26 | — | — | CN | claimed |
| EP-2670750-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | Fibrogen, Inc. (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2012106472-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2012-08-09 | — | — | WO | claimed |
| US-9695170-B2 | Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2670750-B1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR | FIBROGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160159796-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9271970-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150174110-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8921389-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140088101-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| CN-103608346-A | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN INC | 2014-02-26 | — | — | CN | disclosed |
| EP-2670750-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | Fibrogen, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106472-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174110-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885 |
| US-20140088101-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885 |
| US-20160159796-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.